First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis
June 13, 2023 07:00 ET
|
First Wave BioPharma, Inc.
Two-thirds of patients have completed study, final patients being dosedTop line data read-out on track for July 2023 BOCA RATON, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc....
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains
June 07, 2023 01:15 ET
|
Spexis AG
ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...
Spexis provides business update and announces financial results for the full year 2022
May 30, 2023 01:15 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in...
First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference
May 15, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
May 11, 2023 07:00 ET
|
First Wave BioPharma, Inc.
Top line data read-out on track for July 2023 BOCA RATON, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a...
First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference
May 02, 2023 07:30 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., May 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
April 25, 2023 07:00 ET
|
First Wave BioPharma, Inc.
Three U.S. clinical trial sites actively screening and enrolling patientsTop line data of adrulipase in Cystic Fibrosis patients expected in July 2023 BOCA RATON, Fla., April 25, 2023 (GLOBE...
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
April 18, 2023 02:23 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023Commitment...
Cough Assist Devices Market Revenue to Cross USD 480 Mn by 2031 | TMR Study
April 06, 2023 14:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, April 07, 2023 (GLOBE NEWSWIRE) -- The global cough assist devices market size was worth USD 218.5 Mn in 2021 and is expected to exceed value of USD 480.7 Mn by...
Global Spirometer Market is projected to be worth US$ 616 Million in 2023 and is further poised to grow at a CAGR of 5.4% to hit US$ 1042.3 Million by 2033 end | Future Market Insights, Inc.
March 28, 2023 10:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 28, 2023 (GLOBE NEWSWIRE) -- The global spirometer market size is set to reach US$ 616 million in 2023. Overall sales of spirometer are likely to surge at 5.4% CAGR, taking the...